Meta AnalysisID 2547

雷奈酸锶治疗骨关节炎 [Cochrane方案]

CRD42017083045

To assess the benefits and harms of oral strontium ranelate to treat osteoarthritis.

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab

Ingredient: 1Meta-analysis: 1Links: 1

Arranging relationship network...

Record Fields

Scalar fields from the final meta_analysis record.

Meta Analysis Id: 2547
Evidence Id: 11105
Core Evidence Id: 11105
Source Meta Analysis Id: 2495
Herb2 Meta Analysis Id: HBMA002495
Crd Id: CRD42017083045
Title: Strontium ranelate for osteoarthritis [Cochrane protocol]
Review Question: To assess the benefits and harms of oral strontium ranelate to treat osteoarthritis.
Study Type Included: Randomised controlled trials (RCTs). We will include studies reported as full-text articles, those published as abstracts only, and unpublished data. There will be no language restrictions. Given the progressive nature of the disease, we will not consider cross-over trials.
Condition Being Studied: The Cochrane Musculoskeletal Group
Participant: Patients aged 18 or over, with bilateral or unilateral, primary or secondary osteoarthritis (osteoarthritis), in one or more joints, diagnosed according to the American College of Rheumatology criteria (Altman 1986), or with clinically or radiologically confirmed osteoarthritis. We will conduct a subgroup analysis considering different diagnosis criteria.
Animal
Human Disease Modelled
Intervention: Intervention Oral strontium ranelate alone or associated with other medications at any dose and for any course duration. We will not include studies that assess multiple interventions where we cannot analyse the effect of strontium ranelate separately. Comparators No intervention. Placebo. Active pharmacological intervention (e.g. diacerein, glucosamine or chondroitin or both, collagen, herbal medication, or analgesics). Active intra-articular intervention (e.g. hyaluronic acid or corticosteroids). Non-pharmacological intervention (e.g. physical exercises, acupuncture, or physiotherapy).</ul> For technical reasons the intervention and comparators fields for Cochrane protocols are identical and each may include information on both interventions and comparators
Comparator Control: Intervention Oral strontium ranelate alone or associated with other medications at any dose and for any course duration. We will not include studies that assess multiple interventions where we cannot analyse the effect of strontium ranelate separately. Comparators No intervention. Placebo. Active pharmacological intervention (e.g. diacerein, glucosamine or chondroitin or both, collagen, herbal medication, or analgesics). Active intra-articular intervention (e.g. hyaluronic acid or corticosteroids). Non-pharmacological intervention (e.g. physical exercises, acupuncture, or physiotherapy).</ul> For technical reasons the intervention and comparators fields for Cochrane protocols are identical and each may include information on both interventions and comparators
Main Outcome: We will include studies that assess at least one of the following outcomes.<heading level=4>Major outcomes</heading> Pain with a hierarchy of eight levels (when more than one is reported, we will consider the highest on the list). Pain overall. Pain on walking. Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale. Pain on activities other than walking. WOMAC global scale. Lequesne osteoarthritis index global score. Other algofunctional scale. Patient’s global assessment. Physician’s global assessment. Other outcome. No continuous outcome reported.</ul> Physical function with a hierarchy of eight levels (when more than one is reported, we will consider the highest on the list). Global disability score. Walking disability. WOMAC disability subscore. Composite disability scores other than WOMAC. Disability other than walking. WOMAC global scale. Lequesne osteoarthritis index global score. Other algofunctional scale.</ul> Radiographic joint structure changes according to the given hierarchy (when more than one is reported, we will consider the highest on the list). Minimum joint space width. Median joint space width. Semi-quantitative measurement.</ul> Health-related quality of life assessed by specific or generic validated tool, e.g. Health Assessment Questionnaire (HAQ) (<link ref=REF-Fries-1980 type=REFERENCE/>Fries 1980), Short form 36 Health Survey (SF-36) (<link ref=REF-Brazier-1992 type=REFERENCE/>Brazier 1992), EuroQoL; Sickness Impact Profile (SIP); Nottingham Health Profile (NHP) (<link ref=REF-Hunt-1981 type=REFERENCE/>Hunt 1981); other. Proportion of participants who withdraw due to adverse events. Proportion of participants who experience any adverse events. Proportion of participants who experience serious adverse events (those that are immediately life-threatening, or resulted in hospitalisation, incapacity, malignant disease, or death).</ul><heading level=4>Minor outcomes</heading> Participant global assessment of treatment success assessed by any validated tool. We will consider dichotomous, continuous, or Likert-scale data. In this last case, we will dichotomise the categories.</ul><heading level=4>Timing of outcome assessment</heading> We will assess all outcomes listed above at any time point. However, we will only pool similar time points together: short term (up to three months, inclusive) or long term (more than three months).
Outcome Measure
Additional Outcome
Study Method: Intervention, Systematic review
Keyword: Female; Humans; Osteoarthritis; Osteoporosis, Postmenopausal; Thiophenes; strontium ranelate
Contact: Ana Luiza C Martimbianco [email protected]
Organisational Affiliation: The Cochrane Collaboration http://www.cochrane.org/
Funding Source: There were no sources of support related to this protocol There were no sources of support related to this protocol
Other Selection Criteria
Final Publication
Same Topic Review
Published Protocol: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012666/abstract
Review Type
Language: English
Country: Brazil
Review Stage: Review Ongoing
First Submission Date
Registration Date: 2017-12-02
Anticipated Start Date: 2017-05-15
Anticipated Completion Date: 2017-11-01
Title Cn: 雷奈酸锶治疗骨关节炎 [Cochrane方案]
Title En: Strontium ranelate for osteoarthritis [Cochrane protocol]
Bilingual Status: complete